**Online Resource 2 to ’The Cost of Mental Disorders: A systematic review’**

Christensen MK, Lim CCW, Saha S, Plana-Ripoll O, Cannon D, Presley F, Weye N, Momen NC, Whiteford H, Iburg KM, McGrath JJ.

**Contents**

[eTables 2](#_Toc38626177)

[eTable 1: Quality reporting checklist 2](#_Toc38626178)

[eTable 2: Disorder groups ICD-8 & ICD-10 codes 3](#_Toc38626179)

[eTable 3a: Prevalence-based studies 4](#_Toc38626180)

[eTable 3b: Incidence-based studies 9](#_Toc38626181)

[eTable 4: Number of studies by country 10](#_Toc38626182)

[eTable 5: Quality reporting scores by study 13](#_Toc38626183)

[eTabe 6: Direct vs. indirect cost 11](#_Toc38626184)

[eTable 7: Without two multi-site studies 12](#_Toc38626185)

[eTable 8: Societal cost according to quality reporting score 13](#_Toc38626186)

[References 17](#_Toc38626187)

# eTables

## eTable 1: Quality reporting checklist

The quality reporting checklist used in the systematic review was based on a cost-of-illness study checklist by Stuhldreher et al (Stuhldreher *et al.,* 2012). Our revised checklist consisted of 15 items which are seen below together with a short item description. Items were scored 1 or 0 (1 meaning the item was reported), but item number 7 was only relevant for studies with a time period of greater than 1 year. The total score was then standardized to a 10-point scale.

|  |  |
| --- | --- |
| **Criterion** | **Description** |
| Scope and population |  |
| 1. Study objective | The study objective is reported. |
| 1. Disease and diagnostic criteria | The disease and diagnostic criteria (ICD and DSM etc.) that were used to identify eligible patients were reported. |
| 1. Disease and comparison group | Characteristics (at least sample size, age and gender) of the disease group were reported. If the study used a comparison group, it is reported with the same details. |
| Calculation of costs |  |
| 1. Perspective | The perspective of the analysis is reported and justified. |
| 1. Data sources | The sources of epidemiological data, health care utilization and unit costs used were reported. |
| 1. Currency and reference year | The cost currency and reference year were reported. |
| 1. Discounting | Future costs were discounted and the discount rate was given. |
| Study design and analysis |  |
| 1. Costing methods | The costing methods were described in detail. |
| 1. Cost measure | The units of the reported measures were stated (etc. mean annual costs, mean total costs and incremental costs) |
| 1. Missing data and imputation method | The proportion of missing data was reported and if imputation was applied, the method was described. |
| 1. Sensitivity analysis | Parameters used in the sensitivity analysis were justified and they were varied in order to test the robustness of the results for example different unit costs, different assumptions for missing data (completely at random, at random and not at random). |
| 1. Uncertainty estimates | Measurements of uncertainty surrounding the cost estimates are reported (e.g. standard deviations or uncertainty intervals). |
| Discussion |  |
| 1. Results discussed in respect to other studies | The results were discussed in relation to other studies on the same topic, if any existing. |
| 1. Limitations | The limitations, in particular to the calculation of costs, were discussed in detail. |
| 1. Conclusions | The conclusions allowed for the uncertainty inherent to the results. |

## eTable 2: Disorder groups ICD-8 & ICD-10 codes

The table show the codes for different mental disorders groups according to ICD-8 and ICD-10 and the name used in the systematic review. The table also includes the earliest possible age at onset in years for the different disorder groups.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Mental disorders** | **Name used in this study** | **ICD-10** | **ICD-8 equivalency** | **Earliest possible age at onset in years** |
| Mental and behavioral disorders due to psychoactive Substance use | Substance use disorders | F10 - F19 | 291.x9, 294.39, 303.x9, 303.20, 303.28, 303.90, 304.x9 | 10 |
| Schizophrenia | Schizophrenia | F20 - F29 | 295.x9, 296.89, 297.x9, 298.29-298.99, 299.04, 299.05, 299.09, 301.83 | 10 |
| Mood disorders | Mood disorders | F30 - F39 | 296.x9 (excluding 296.89), 298.09, 298.19, 300.49, 301.19 | 10 |
| Neurotic, stress-related, and somatoform disorders | Neurotic disorders | F40 - F48 | 300.x9 (excluding 300.49), 305.x9, 305.68, 307.99 | 5 |
| Eating disorders | Eating disorders | F50 | 306.50, 306.58, 306.59 | 1 |
| Specific personality disorders | Personality disorders | F60 | 301.x9 (excluding 301.19), 301.80, 301.81, 301.82, 301.84 | 10 |
| Intellectual Disabilities | Intellectual Disabilities | F70 - F79 | 311.xx, 312.xx, 313.xx, 314.xx, 315.xx | 1 |
| Pervasive developmental disorders | Developmental disorders | F84 | 299.00, 299.01, 299.02, 299.03 | 1 |
| Behavioral and emotional disorders with onset usually occurring in childhood and adolescence | Behavioral disorders | F90 - F98 | 306.x9, 308.0x | 1 |
| All groups | More than one mental disorder group | F10-48, F50, F60, F70-F79, F84, F90-98 |  |  |

## eTable 3a: Prevalence-based studies

eTable 3a and 3b describes the included studies by author(s), year of publication, epidemiological approach, cost categories, diagnostic criteria, reference year and currency.

| **Study** | **Cost category** | **Disorder group** | **Diagnostic criteria** | **Reference year** | **Currency** |
| --- | --- | --- | --- | --- | --- |
| Amaddeo *et al.,* 1997 | direct | mood disorders | ICD-10 | 1993 | ITL |
| Andlin Sobocki *et al.,* 2005 | direct & indirect | 2+ disorders | DSM-5, ICD-10 | 2004 | EUR |
| Balakrishnan *et al.,* 2009 | direct | substance use | ICD | 2005 | GBP |
| Bell *et al.,* 2004 | direct & indirect | mood disorders | DSM-IV | 2003 | CAD |
| Bendeck *et al.,* 2013 | direct | mood disorders | ICD-9-CM, ICD-10 | 2006 | EUR |
| Birnbaum *et al.,* 2006 | direct & indirect | substance use | DSM-IV | 2001 | USD |
| Bock *et al.,* 2016 | direct | mood disorders | ICD-10 | 2012 | EUR |
| Bode *et al.,* 2017 | direct | 2+ disorders | ICD-10-GM | 2010 | EUR |
| Bosmans *et al.,* 2010 | direct | mood disorders | ICPC-2 | 2003 | EUR |
| Bourke *et al.,* 2018 | direct | personality disorders | DSM-IV, ICD-10 | 2014 | EUR |
| Braun *et al.,* 2013 | direct | behavioural disorders | ICD-10 | 2008 | EUR |
| Brecht *et al.,* 1996 | direct & indirect | substance use | ICD-9 | 1990 | DEM |
| Burd *et al.,* 2003 | direct | behavioural disorders | ICD-9, DSM-IV | 1996 | USD |
| Byford *et al.,* 2011 | direct | mood disorders | ICD-9-CM | 2006 | GBP |
| Carr *et al.,* 2003 | direct & indirect | 2+ disorders | ICD-10 | 2000 | AUD |
| Casadei *et al.,* 2017 | direct | behavioural disorders | DSM-IV-TR | 2015 | EUR |
| Chan *et al.,* 2002 | direct | behavioural disorders | ICD-9-CM | 1996 | USD |
| Chang *et al.,* 2008 | direct & indirect | 2+ disorders | ICD-10 | 2005 | USD |
| Chang *et al.,* 2012 | direct & indirect | 2+ disorders | ICD-10 | 2005 | USD |
| Chevreul *et al.,* 2013 | direct, indirect & intangible | 2+ disorders | ICD-10 | 2007 | EUR |
| Chiavegatto Filho *et al.,* 2015 | direct | 2+ disorders | DSM-IV | 2007 | BRL |
| Chiu *et al.,* 2017 | direct | mood disorders | ICD-9, ICD-10, DSM-IV | 2013 | USD |
| Cidav *et al.,* 2012 | indirect | developmental disorders | ICD-9 | 2011 | USD |
| Cloutier *et al.,* 2016 | direct & indirect | schizophrenia | ICD-9 | 2013 | USD |
| Croft-Jeffreys and Wilkinson, 1989 | direct & indirect | neurotic disorders | ICD-9 | 1985 | GBP |
| Dams *et al.,* 2017 | direct & indirect | neurotic disorders | DSM-IV | 2014 | EUR |
| Das Gupta and Guest, 2002 | direct & indirect | mood disorders | READ codes, ICD-10 | 1999 | GBP |
| de Oliveira *et al.,* 2017 | direct | eating disorders | ICD-9, ICD-10, DSM-IV | 2012 | CAD |
| Degli Esposti *et al.,* 2014 | direct | 2+ disorders | ICD-9, ICD-10 | 2009 | EUR |
| Dilsaver, 2011 | direct & indirect | mood disorders | DSM-IV | 2009 | USD |
| DuPont *et al.,* 1996 | direct & indirect | neurotic disorders | DSM-III-R, ICD-9-CM | 1990 | USD |
| Ekman *et al.,* 2013a | direct & indirect | mood disorders | ICD-10 | 2008 | EUR |
| Ekman *et al.,* 2013b | direct & indirect | mood disorders | ICD-10 | 2008 | EUR |
| Evensen *et al.,* 2015 | direct & indirect | schizophrenia | ICD-10 | 2012 | USD |
| Ewest *et al.,* 2013 | direct | behavioural disorders | ICD-10 | 2012 | EUR |
| Ferry *et al.,* 2015 | direct & indirect | neurotic disorders | DSM-IV | 2008 | GBP |
| Fineberg *et al.,* 2013 | direct & indirect | neurotic disorders | DSM-III, DSM-IIIR, DSMIV, ICD-10 | 2010 | EUR |
| Fisher *et al.,* 2007 | direct & indirect | mood disorders | DSM-IV | 2004 | AUD |
| Fitzgerald *et al.,* 2007 | direct & indirect | schizophrenia | DSM-IV | 1999 | AUD |
| Florence *et al.,* 2016 | direct & indirect | substance use | ICD-9-CM | 2013 | USD |
| Frey, 2014 | direct & indirect | schizophrenia | ICD-10-GM | 2008 | EUR |
| Ganz, 2007 | direct & indirect | developmental disorders | ICD-9 | 2003 | USD |
| Gerhardt *et al.,* 2018 | direct | behavioural disorders | ICD-10 | 2011 | EUR |
| Greenberg *et al.,* 2003 | direct & indirect | mood disorders | DSM-IV | 2000 | USD |
| Greenberg *et al.,* 1999 | direct & indirect | neurotic disorders | DSM-III-R | 1990 | USD |
| Gupte-Singh *et al.,* 2017 | direct & indirect | behavioural disorders | ICD-9-CM | 2011 | USD |
| Gustavsson *et al.,* 2011 | direct & indirect | 2+ disorders | ICD-10 | 2010 | EUR |
| Hakkaart-van Roijen *et al.,* 2007 | direct | behavioural disorders | DSM-IV | 2004 | EUR |
| Hawthorne *et al.,* 2003 | direct, indirect & intangible | mood disorders | DSM-IV | 1998 | AUD |
| Hertzman, 1983 | direct | 2+ disorders | ICD-8 | 1975 | SEK |
| Hjortsberg *et al.,* 2011 | direct & indirect | schizophrenia | ICD-10 | 2007 | EUR |
| Hu *et al.,* 2007 | direct & indirect | mood disorders | DSM-IV | 2002 | RMB |
| Jarbrink and Knapp, 2001 | direct & indirect | developmental disorders | DSM-IV | 1997 | GBP |
| Kilian *et al.,* 2001 | direct | schizophrenia | ICD-10 | 1998 | DEM |
| Kind and Sorensen, 1993 | direct & indirect | mood disorders | ICD | 1990 | GBP |
| Kleine-Budde *et al.,* 2013 | direct | mood disorders | ICD-10 | 2009 | EUR |
| Klora *et al.,* 2015 | direct | behavioural disorders | ICD-10-GM | 2007 | EUR |
| Knapp *et al.,* 2002 | direct | schizophrenia | ICD-10 | 1998 | GBP |
| Krauth *et al.,* 2002 | direct & indirect | eating disorders | ICD-10 | 1998 | EUR |
| Laidi *et al.,* 2018 | direct | schizophrenia | DSM-IV-TR | 2015 | EUR |
| Lang and Su, 2004 | direct | schizophrenia | ICD-9-CM | 1999 | USD |
| Lee *et al.,* 2017 | direct & indirect | 2+ disorders | ICD-10 | 2013 | AUD |
| Libutzki *et al.,* 2019 | direct | behavioural disorders | ICD-10-GM | 2014 | EUR |
| Lima and Esquerdo, 2003 | direct & indirect | substance use | ICD-9-CM | 1995 | EUR |
| Lin *et al.,* 2011 | direct | developmental disorders | ICD-9-CM | 2005 | NTD |
| Lin *et al.,* 2013 | direct | developmental disorders | ICD-9-CM | 2005 | NTD |
| Ling *et al.,* 2017 | direct & indirect | eating disorders | DSM-5 | 2013 | USD |
| Liptak *et al.,* 2006 | direct | 2+ disorders | ICD-9-CM | 1999 | USD |
| Lund *et al.,* 2013 | indirect | 2+ disorders | DSM-IV | 2012 | EUR |
| Lunsky *et al.,* 2019 | direct | intellectual disabilities | ICD | 2009 | CAD |
| Maercker *et al.,* 2013 | direct & indirect | 2+ disorders | ICD-10, DSM-III-R/DSM-IV | 2010 | EUR |
| Mangalore and Knapp, 2007 | direct & indirect | schizophrenia | DSM-IV | 2004 | GBP |
| Manthey *et al.,* 2016 | direct & indirect | substance use | DSM-IV | 2014 | EUR |
| Mark *et al.,* 2000 | direct | substance use | ICD-9 | 1997 | USD |
| Masís *et al.,* 2010 | direct | mood disorders | ICD-10, DSM-IV-TR | 2010 | MXN |
| Mennini *et al.,* 2014 | indirect | mood disorders | DSM-IV | 2012 | EUR |
| Moreno *et al.,* 2006 | direct & indirect | neurotic disorders | ICD-9-MC | 2002 | EUR |
| Nakamura and Takano, 1993 | direct & indirect | substance use | ICD-9 | 1987 | JPY |
| Neil *et al.,* 2014 | direct & indirect | schizophrenia | ICD-10 | 2010 | AUD |
| Okumura and Higuchi, 2011 | direct & indirect | mood disorders | ICD-10 | 2008 | USD |
| Olesen *et al.,* 2012 | direct & indirect | 2+ disorders | ICD-10, DSM-IV | 2010 | EUR |
| Oliva-Moreno *et al.,* 2006 | direct & indirect | schizophrenia | ICD-9 | 2002 | EUR |
| Opoku-Boateng *et al.,* 2017 | direct & indirect | schizophrenia | ICD-10 | 2016 | USD |
| Ösby *et al.,* 2009 | direct | mood disorders | ICD-10 | 2005 | EUR |
| Pamias Massana *et al.,* 2012 | direct & indirect | mood disorders | ICD-9, ICD-10 | 2008 | EUR |
| Pares-Badell *et al.,* 2014 | direct & indirect | neurotic disorders | ICD-10 | 2010 | EUR |
| Patel *et al.,* 2002 | direct & indirect | neurotic disorders | ICD-10 | 1998 | GBP |
| Phanthunane *et al.,* 2012 | direct & indirect | schizophrenia | ICD-10 | 2008 | THB |
| Pletscher *et al.,* 2015 | direct & indirect | schizophrenia | ICD-10 | 2012 | EUR |
| Quintero *et al.,* 2018 | direct & indirect | behavioural disorders | DSM-IV | 2012 | EUR |
| Rice and Miller, 1998 | direct & indirect | 2+ disorders | ICD-9, DSM-III | 1990 | USD |
| Ritter *et al.,* 2015 | direct | substance use | ICD | 2012 | AUD |
| Rouillon *et al.,* 1997 | direct | schizophrenia | DSM-III-R | 1992 | USD |
| Rovira *et al.,* 2012 | direct & indirect | neurotic disorders | ICD-9, ICD-10 | 2006 | EUR |
| Runge and Grunze, 2004 | direct & indirect | mood disorders | ICD-10, DSM-IV | 2002 | EUR |
| Sado, 2014 | direct & indirect | mood disorders | DSM-IV | 2005 | JPY |
| Sado *et al.,* 2013 | direct & indirect | schizophrenia | ICD-10 | 2008 | JPY |
| Salvador-Carulla *et al.,* 2014 | direct & indirect | personality disorders | ICD-9, ICD-10 | 2006 | EUR |
| Salvador-Carulla *et al.,* 2011 | direct & indirect | mood disorders | ICD-10 | 2006 | EUR |
| Samnaliev *et al.,* 2015 | direct | eating disorders | ICD-9 | 2011 | USD |
| Sandelin *et al.,* 2013 | direct | neurotic disorders | ICD-10 | 2008 | SEK |
| Sarlon *et al.,* 2012 | direct & indirect | schizophrenia | DSM-IV | 2005 | EUR |
| Schlander, 2007 | direct | behavioural disorders | ICD-10 | 2012 | GBP |
| Schofield *et al.,* 2011 | indirect | mood disorders | ICD-10 | 2009 | AUD |
| Sharma *et al.,* 2006 | direct & indirect | schizophrenia | DIGS | 2002 | INR |
| Shei *et al.,* 2015 | direct | substance use | ICD-9-CM | 2013 | EUR |
| Shirneshan, 2014 | direct & indirect | neurotic disorders | ICD-9-CM | 2013 | USD |
| Slomp *et al.,* 2012 | direct | mood disorders | ICD-9-CM, ICD-10 | 2007 | CAD |
| Smit *et al.,* 2006 | direct & indirect | 2+ disorders | DSM-III-R | 2003 | EUR |
| Sobocki *et al.,* 2007 | direct, indirect & intangible | mood disorders | ICD-10 | 2005 | EUR |
| Soeteman *et al.,* 2008 | direct & indirect | personality disorders | DSM-III-R, DSM-IV | 2005 | EUR |
| Souêtre *et al.,* 1994 | direct & indirect | neurotic disorders | DSM-III-R | 1993 | USD |
| Stoudemire *et al.,* 1986 | direct & indirect | mood disorders | DIS | 1980 | USD |
| Strydom *et al.,* 2010 | direct | intellectual disabilities | ICD-10 | 2006 | GBP |
| Suleiman *et al.,* 1997 | direct | schizophrenia | ICD-10 | 1995 | NGN |
| Sundhedsministeriet [Ministry of Health], 1999 | direct | substance use | ICD-9-CM | 1999 | DKK |
| Telford *et al.,* 2013 | direct & indirect | behavioural disorders | DSM-IV, ICD-10 | 2010 | GBP |
| Teoh *et al.,* 2017 | direct & indirect | schizophrenia | DSM-5 | 2015 | USD |
| Thomas and Morris, 2003 | direct & indirect | mood disorders | ICD-9, ICD-10 | 2000 | GBP |
| Tiainen and Rehnberg, 2010 | direct & indirect | 2+ disorders | ICD-10 | 2001 | EUR |
| Tomonaga *et al.,* 2013 | direct & indirect | mood disorders | ICD-10 | 2010 | EUR |
| Trivedi *et al.,* 2004 | direct & indirect | mood disorders | ICD-9-CM | 1999 | USD |
| Trogdon *et al.,* 2015 | direct & indirect | mood disorders | ICD-9-CM | 2010 | USD |
| Vasiliadis *et al.,* 2013 | direct | 2+ disorders | DSM-IV | 2006 | CAD |
| Vazquez-Polo *et al.,* 2005 | direct | schizophrenia | DSM-IV | 1999 | EUR |
| Vodušek *et al.,* 2008 | direct & indirect | 2+ disorders | ICD-10 | 2004 | EUR |
| Wagner *et al.,* 2016 | direct | mood disorders | ICD-10 | 2010 | EUR |
| Wancata *et al.,* 2007 | direct & indirect | 2+ disorders | ICD, DSM | 2004 | EUR |
| Young *et al.,* 2011 | direct | mood disorders | ICD-10 | 2009 | GBP |
| Zeidler *et al.,* 2012 | direct | schizophrenia | ICD-10 | 2006 | EUR |
| Zuvekas and Meyerhoefer, 2009 | direct | substance use | ICD-9-CM | 2005 | USD |

## eTable 3b: Incidence-based studies

| **Study** | **Cost category** | **Disorder group** | **Diagnostic criteria** | **Reference year** | **Currency** |
| --- | --- | --- | --- | --- | --- |
| Begley *et al.,* 2001 | direct and indirect | mood disorders | DSM-III-R | 1998 | USD |
| Bereza *et al.,* 2012 | direct and indirect | neurotic disorders | DSM-IV, ICD-10 | 2008 | CAD |
| Chisholm *et al.,* 2003 | direct | mood disorders | DSM-IV | 2000 | ILS |
| Chollet *et al.,* 2013 | direct | neurotic disorders | READ codes | 2010 | GBP |
| Florence *et al.,* 2016 | direct and indirect | substance use | ICD-9-CM | 2013 | USD |
| Guest and Cookson, 1999 | direct and indirect | schizophrenia | ICD-7, ICD-8, ICD-9 | 1997 | GBP |
| Hall *et al.,* 1985 | direct and indirect | schizophrenia | DSM-III, ICD-8 | 1975 | USD |
| Hastrup *et al.,* 2019 | direct and indirect | schizophrenia | ICD-10 | 2016 | EUR |
| Heider *et al.,* 2009 | direct | schizophrenia | DSM-IV | 2000 | EUR |
| Holden *et al.,* 2013 | direct | behavioural disorders | Read-codes | 2009 | GBP |
| Kortmann *et al.,* 2017 | indirect | schizophrenia | ICD-10 | 2012 | EUR |
| Kujanpaa *et al.,* 2014 | direct | 2+ disorders | ICD-10 | 2007 | EUR |
| Langley-Hawthorne, 1997 | direct and indirect | schizophrenia | DSM-III | 1995 | AUD |

## eTable 4: Number of studies by country

The number of studies by country is shown in the table. The same study could provide estimates for more than one country. Consequently, the aggregated number of studies exceeds the number (143) of included studies in the systematic review. There was a markedly variation by country, where high-income countries had more COI-studies about mental disorders.

|  |  |
| --- | --- |
| **Country** | **Number of studies** |
| Australia | 11 |
| Austria | 3 |
| Belgium | 2 |
| Brazil | 2 |
| Bulgaria | 1 |
| Canada | 7 |
| China | 1 |
| Colombia | 1 |
| Cyprus | 2 |
| Czech Republic | 2 |
| Denmark | 5 |
| Estonia | 2 |
| Europe | 3 |
| Finland | 3 |
| France | 9 |
| Germany | 23 |
| Ghana | 1 |
| Greece | 2 |
| Hungary | 2 |
| Iceland | 2 |
| India | 1 |
| Ireland | 3 |
| Israel | 1 |
| Italy | 8 |
| Japan | 4 |
| Latvia | 2 |
| Lithuania | 2 |
| Luxembourg | 2 |
| Malaysia | 1 |
| Malta | 2 |
| Netherlands | 7 |
| Nigeria | 1 |
| Norway | 3 |
| Poland | 2 |
| Portugal | 3 |
| Romania | 1 |
| Russia | 1 |
| Slovakia | 2 |
| Slovenia | 3 |
| South Africa | 1 |
| South Korea | 2 |
| Spain | 15 |
| Sweden | 10 |
| Switzerland | 4 |
| Taiwan | 3 |
| Thailand | 1 |
| United Kingdom | 23 |
| United States | 24 |

## eTabe 5: Direct vs. indirect cost

16 distinct studies reported direct and indirect cost from the total societal costs. On average, direct cost constituted 52 % and indirect cost 48 % of the total societal costs. The table below show the percentages divided by disorder group.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Mental disorder group | Number of studies\* | Number of estimates\*\* | Direct cost | Indirect cost |
| Substance use | 4 | 15 | 66 % | 34 % |
| Schizophrenia | 7 | 21 | 45 % | 55 % |
| Personality disorders | 2 | 9 | 21 % | 79 % |
| Neurotic disorders | 5 | 30 | 58 % | 42 % |
| Mood disorders | 6 | 21 | 47 % | 53 % |
| Eating disorders | 2 | 9 | 74 % | 26 % |

Notes:  
\* Some studies reported estimates for more than one disorder group.

\*\* Some studies reported estimates for more than one country.

## eTable 6: Without two multi-site studies

The univariate statistics were calculated for the societal cost per patient without the two multi-site studies, Andlin-Sobocki *et al.,* 2005) and Gustavsson *et al.,* 2011) to investigate their influence on the results.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Societal cost per patient (USD PPP 2018)** | | | | | | | |
| Disorder group | N | Median | Mean | Min. | Max. | 1st Qu. | 3rd Qu. |
| Substance use | 7 | 3,716 | 4,438 | 798 | 10,205 | 3,563 | 4,612 |
| Schizophrenia | 13 | 34,588 | 40,438 | 8,073 | 96,466 | 21,500 | 52,312 |
| Mood disorders | 13 | 7,728 | 10,640 | 158 | 40,045 | 3,492 | 13,969 |
| Neurotic disorders | 13 | 1,287 | 2,619 | 838 | 13,862 | 1,180 | 1,619 |
| Eating disorders | 4 | 859 | 9,985 | 41 | 38,183 | 509 | 10,335 |
| Personality disorders | 3 | 6,855 | 6,668 | 3,547 | 9,602 | 5,201 | 8,229 |
| Intellectual disabilities | - | - | - | - | - | - | - |
| Developmental disorders | 2 | 16,783 | 16,783 | 4,236 | 29,330 | 10,509 | 23,056 |
| Behavioural disorders | 5 | 2,151 | 5,347 | 840 | 12,588 | 1,867 | 9,290 |
| N = number of estimates (etc. one study can include several estimates for different countries) | | | | | | | |

## eTable 7: Quality reporting scores by study

The quality reporting scores are presented in the table below together with author and publication year. 0 indicates the item was not reported, and 1 indicates it was reported. NA means the item is not applicable (only relevant for item 7 about discounting). The column ‘Score’ contains the total score on a standardized 10-point scale.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Authors | Year | 1. | 2. | 3. | 4. | 5. | 6. | 7. | 8. | 9. | 10. | 11. | 12. | 13. | 14. | 15. | Score |
| Amaddeo et al | 1997 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 6 |
| Andlin‐Sobocki et al | 2005 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 7 |
| Balakrishnan et al | 2009 | 1 | 0 | 0 | 0 | 1 | 1 | NA | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 6 |
| Begley et al | 2001 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 9 |
| Bell et al | 2004 | 1 | 1 | 1 | 0 | 1 | 0 | NA | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 4 |
| Bendeck et al | 2013 | 1 | 1 | 0 | 1 | 1 | 1 | NA | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 9 |
| Bereza et al | 2012 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 8 |
| Birnbaum et al | 2006 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 7 |
| Bock et al | 2016 | 1 | 1 | 1 | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 |
| Bode et al | 2017 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 8 |
| Bosmans et al | 2010 | 1 | 1 | 1 | 1 | 1 | 1 | NA | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 9 |
| Bourke et al | 2018 | 1 | 1 | 1 | 1 | 0 | 1 | NA | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 9 |
| Braun et al | 2013 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 7 |
| Brecht et al | 1996 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 6 |
| Burd et al | 2003 | 1 | 1 | 1 | 0 | 1 | 1 | NA | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 5 |
| Byford et al | 2011 | 1 | 1 | 1 | 1 | 1 | 1 | NA | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 7 |
| Carr et al | 2003 | 1 | 1 | 0 | 1 | 1 | 1 | NA | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 8 |
| Casadei et al | 2017 | 1 | 1 | 1 | 1 | 1 | 1 | NA | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 7 |
| Chan et al | 2002 | 1 | 1 | 1 | 0 | 0 | 1 | NA | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 6 |
| Chang et al | 2008 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 7 |
| Chang et al | 2012 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 7 |
| Chevreul et al | 2013 | 1 | 1 | 0 | 1 | 1 | 1 | NA | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 7 |
| Chiavegatto Filho et al | 2015 | 1 | 1 | 1 | 0 | 1 | 1 | NA | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 6 |
| Chisholm et al | 2003 | 1 | 1 | 0 | 0 | 1 | 1 | NA | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 7 |
| Chiu et al | 2017 | 1 | 1 | 0 | 0 | 1 | 1 | NA | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 8 |
| Chollet et al | 2013 | 1 | 1 | 1 | 0 | 1 | 1 | NA | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 7 |
| Cidav et al | 2012 | 1 | 1 | 0 | 1 | 0 | 0 | NA | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 5 |
| Cloutier et al | 2016 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 7 |
| Croft-Jeffreys, C and Wilkinson, G | 1989 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 5 |
| Dams et al | 2017 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Das Gupta & Guest | 2002 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 8 |
| de Oliveira et al | 2017 | 1 | 1 | 1 | 1 | 1 | 1 | NA | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 9 |
| Degli Esposti et al | 2014 | 1 | 1 | 1 | 0 | 1 | 1 | NA | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 7 |
| Dilsaver | 2011 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 5 |
| DuPont et al | 1996 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 7 |
| Ekman et al | 2013a | 1 | 1 | 1 | 1 | 1 | 1 | NA | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 8 |
| Ekman et al | 2013b | 1 | 1 | 1 | 1 | 1 | 1 | NA | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 8 |
| Evensen et al | 2015 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 8 |
| Ewest et al | 2013 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 6 |
| Ferry et al | 2015 | 1 | 1 | 1 | 1 | 1 | 1 | NA | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 9 |
| Fineberg et al | 2013 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 6 |
| Fisher et al | 2007 | 1 | 1 | 0 | 1 | 1 | 1 | NA | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 8 |
| Fitzgerald et al | 2007 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 6 |
| Florence et al | 2016 | 1 | 1 | 0 | 1 | 1 | 1 | NA | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 7 |
| Frey, S | 2014 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 |
| Ganz | 2007 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 7 |
| Gerhardt et al | 2018 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 7 |
| Greenberg et al | 1999 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 7 |
| Greenberg et al | 2003 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 6 |
| Guest & Cookson | 1999 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 7 |
| Gupte-Singh et al | 2017 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Gustavsson et al | 2011 | 1 | 1 | 0 | 1 | 1 | 1 | NA | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 8 |
| Hakkaart-van Roijen et al | 2007 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 9 |
| Hall et al | 1985 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 8 |
| Hastrup et al | 2019 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 7 |
| Hawthorne et al | 2003 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 7 |
| Heider et al | 2009 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 6 |
| Hertzman, Peter | 1983 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 5 |
| Hjortsberg et al | 2011 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 8 |
| Holden et al | 2013 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 7 |
| Hu et al | 2007 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 7 |
| Jarbrink & Knapp | 2001 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 6 |
| Kilian et al | 2001 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 3 |
| Kind & Sorensen | 1993 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 4 |
| Kleine-Budde et al | 2013 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 7 |
| Klora et al | 2015 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 7 |
| Knapp et al | 2002 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 7 |
| Kortmann et al | 2017 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 7 |
| Krauth et al | 2002 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 6 |
| Kujanpaa et al | 2014 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 5 |
| Laidi et al | 2018 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Lang et al | 2004 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 7 |
| Langley-Hawthorne | 1997 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 5 |
| Lee et al | 2017 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 7 |
| Libutzki et al | 2019 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 8 |
| Lima et al | 2003 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 7 |
| Lin et al | 2011 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 5 |
| Lin et al | 2013 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 7 |
| Ling et al | 2017 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 8 |
| Liptak et al | 2006 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 7 |
| Lund et al | 2013 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 8 |
| Lunsky et al | 2019 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 6 |
| Maercker et al | 2013 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 7 |
| Mangalore & Knapp | 2007 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 7 |
| Manthey et al | 2016 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Mark et al | 2000 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 6 |
| Masís et al | 2010 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 7 |
| Mennini et al | 2014 | 1 | 1 | 1 | 0 | 1 | 1 | NA | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Moreno et al | 2006 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 7 |
| Nakamura & Takano | 1993 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 7 |
| Neil et al | 2014 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 8 |
| Okumura & Higuchi | 2011 | 1 | 1 | 0 | 1 | 1 | 1 | NA | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 8 |
| Olesen et al | 2012 | 1 | 1 | 0 | 0 | 1 | 1 | NA | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 7 |
| Oliva-Moreno et al | 2006 | 1 | 1 | 0 | 1 | 1 | 1 | NA | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 6 |
| Opoku-Boateng et al | 2017 | 1 | 1 | 1 | 1 | 1 | 1 | NA | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 7 |
| Pamias Massana et al | 2012 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 7 |
| Pares-Badell et al | 2014 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 7 |
| Patel et al | 2002 | 1 | 1 | 1 | 1 | 1 | 1 | NA | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 8 |
| Phanthunane et al | 2012 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |
| Pletscher et al | 2015 | 1 | 1 | 0 | 1 | 1 | 1 | NA | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 8 |
| Quintero et al | 2018 | 1 | 1 | 1 | 1 | 1 | 1 | NA | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 8 |
| Rice & Miller | 1998 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 7 |
| Ritter & Berends | 2015 | 1 | 1 | 0 | 0 | 1 | 1 | NA | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 5 |
| Rouillon et al | 1997 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 7 |
| Rovira et al | 2012 | 1 | 1 | 1 | 1 | 1 | 1 | NA | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 9 |
| Runge & Grunze | 2004 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 7 |
| Sado | 2014 | 1 | 1 | 0 | 0 | 1 | 1 | NA | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 7 |
| Sado et al | 2013 | 1 | 1 | 0 | 1 | 1 | 1 | NA | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 9 |
| Salvador-Carulla et al | 2014 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 9 |
| Salvador-Carulla et al | 2011 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 9 |
| Samnaliev et al | 2015 | 1 | 1 | 1 | 0 | 0 | 1 | NA | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 6 |
| Sandelin et al | 2013 | 1 | 1 | 1 | 0 | 1 | 1 | NA | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 6 |
| Sarlon et al | 2012 | 1 | 1 | 1 | 0 | 1 | 1 | NA | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 7 |
| Schlander | 2007 | 1 | 1 | 0 | 1 | 1 | 1 | NA | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 8 |
| Schofield et al | 2011 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 8 |
| Sharma et al | 2006 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 6 |
| Shei et al | 2015 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 7 |
| Shirneshan E | 2014 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 9 |
| Slomp et al | 2012 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 5 |
| Smit et al | 2006 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 7 |
| Sobocki et al | 2007 | 1 | 1 | 0 | 1 | 0 | 1 | NA | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 6 |
| Soeteman et al | 2008 | 1 | 1 | 1 | 1 | 1 | 1 | NA | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 9 |
| Souêtre et al | 1994 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 7 |
| Stoudemire et al | 1986 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 5 |
| Strydom et al | 2010 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 9 |
| Suleiman et al | 1997 | 1 | 1 | 0 | 0 | 1 | 1 | NA | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 6 |
| Sundhedsministeriet [Ministry of Health] | 1999 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |
| Telford et al | 2013 | 1 | 1 | 1 | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 |
| Teoh et al | 2017 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 9 |
| Thomas et al | 2003 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 7 |
| Tiainen & Rehnberg | 2010 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 8 |
| Tomonaga et al | 2013 | 1 | 1 | 1 | 1 | 1 | 1 | NA | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 9 |
| Trivedi et al | 2004 | 1 | 1 | 0 | 0 | 1 | 1 | NA | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 4 |
| Trogdon et al | 2015 | 1 | 1 | 0 | 0 | 1 | 1 | NA | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 6 |
| Vasiliadis et al | 2013 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 6 |
| Vazquez-Polo et al | 2005 | 1 | 1 | 1 | 1 | 1 | 1 | NA | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 9 |
| Vodušek et al | 2008 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 5 |
| Wagner et al | 2016 | 1 | 1 | 1 | 0 | 1 | 1 | NA | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 8 |
| Wancata et al | 2007 | 1 | 1 | 0 | 1 | 0 | 1 | NA | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 6 |
| Young et al | 2011 | 1 | 1 | 0 | 0 | 1 | 1 | NA | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 6 |
| Zeidler et al | 2012 | 1 | 1 | 1 | 1 | 1 | 1 | NA | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 8 |
| Zuvekas & Meyerhoefer | 2009 | 1 | 0 | 0 | 1 | 0 | 1 | NA | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 4 |
| Ösby et al | 2009 | 1 | 1 | 1 | 0 | 1 | 1 | NA | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 6 |

Note: the scores have been standardized to a 10-point scale.

## eTable 8: Societal cost in studies with high quality reporting scores

Studies with a quality reporting score below 7 were excluded to investigate their influence on the univariate statistics and the figures for societal mean costs per patient.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Societal cost per patient (USD PPP 2018)** | | | | | | | |
| Disorder group | N | Median | Mean | Min. | Max. | 1st Qu. | 3rd Qu. |
| Substance use | 93 | 4,755 | 5,091 | 798 | 11,944 | 2,986 | 6,522 |
| Schizophrenia | 67 | 12,727 | 16,771 | 3,255 | 71,878 | 8,050 | 20,590 |
| Mood disorders | 96 | 4,443 | 5,670 | 888 | 40,045 | 2,835 | 6,949 |
| Neurotic disorders | 214 | 933 | 1,161 | 128 | 13,862 | 552 | 1499 |
| Eating disorders | 33 | 535 | 1,658 | 41 | 38,183 | 320 | 700 |
| Personality disorders | 32 | 5,663 | 5,796 | 1,637 | 10,051 | 3,513 | 7,664 |
| Intellectual disabilities | 30 | 10,105 | 9,762 | 3,052 | 22,040 | 6,431 | 12,174 |
| Developmental disorders | 1 | 29,330 | 29,330 | 29,330 | 29,330 | 29,330 | 29,330 |
| Behavioural disorders | 4 | 2,009 | 3,537 | 840 | 9,290 | 1,610 | 3,936 |
| Developmental & behavioural disorders | 30 | 3,564 | 3,672 | 1,368 | 9,473 | 2,621 | 4,142 |
| N = number of estimates (etc. one study can include several estimates for different countries) | | | | | | | |

# References

**Amaddeo F, Beecham J, Bonizzato P, Fenyo A, Knapp M and Tansella M**. (1997) The use of a case register to evaluate the costs of psychiatric care. *Acta Psychiatrica Scandinavica* **95**: 189-198.

**Andlin-Sobocki P, Jönsson B, Wittchen HU and Olesen J**. (2005) Cost of disorders of the brain in Europe. *European Journal of Neurology* **12**: 1-27.

**Balakrishnan R, Allender S, Scarborough P, Webster P and Rayner M**. (2009) The burden of alcohol-related ill health in the United Kingdom. *Journal of Public Health (Oxford)* **31**: 366-373.

**Begley CE, Annegers JF, Swann AC, Lewis C, Coan S, Schnapp WB and Bryant-Comstock L**. (2001) The lifetime cost of bipolar disorder in the US. *Pharmacoeconomics* **19**: 483-495.

**Bell B, Chalklin L, Mills M, Browne G, Steiner M, Roberts J, Gafni A, Byrne C, Wallik D, Kraemer J, Webb M, Jamieson E, Whittaker S and Dunn E**. (2004) Burden of dysthymia and comorbid illness in adults in a Canadian primary care setting: high rates of psychiatric illness in the offspring. *Journal of Affective Disorders* **78**: 73-80.

**Bendeck M, Serrano-Blanco A, Garcia-Alonso C, Bonet P, Jorda E, Sabes-Figuera R, Salvador-Carulla L and Costdep G**. (2013) An integrative cross-design synthesis approach to estimate the cost of illness: An applied case to the cost of depression in Catalonia. *Journal of Mental Health* **22**: 135-154.

**Bereza BG, Machado M, Papadimitropoulos M, Sproule B, Ravindran AV and Einarson TR**. (2012) A Markov Model Approach Assessing the Cost of Illness of Generalized Anxiety Disorder in Canada. *Neurology and Therapy* **1**: 1-17.

**Birnbaum HG, White AG, Reynolds JL, Greenberg PE, Zhang M, Vallow S, Schein JR and Katz NP**. (2006) Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective. *The Clinical Journal of Pain* **22**: 667-676.

**Bock JO, Brettschneider C, Weyerer S, Werle J, Wagner M, Maier W, Scherer M, Kaduszkiewicz H, Wiese B, Moor L, Stein J, Riedel-Heller SG and Konig HH**. (2016) Excess health care costs of late-life depression - Results of the AgeMooDe study. *Journal of Affective Disorders* **199**: 139-147.

**Bode K, Vogel R, Walker J and Kroger C**. (2017) Health care costs of borderline personality disorder and matched controls with major depressive disorder: a comparative study based on anonymized claims data. *European Journal of Health Economics* **18**: 1125-1135.

**Bosmans JE, de Bruijne MC, de Boer MR, van Hout H, van Steenwijk P and van Tulder MW**. (2010) Health care costs of depression in primary care patients in The Netherlands. *Family Practice* **27**: 542-548.

**Bourke J, Murphy A, Flynn D, Kells M, Joyce M and Hurley J**. (2018) Borderline personality disorder: resource utilisation costs in Ireland. *Irish Journal of Psychological Medicine*: 1-8.

**Braun S, Zeidler J, Linder R, Engel S, Verheyen F and Greiner W**. (2013) Treatment costs of attention deficit hyperactivity disorder in Germany. *The European Journal of Health Economics* **14**: 939-945.

**Brecht JG, Poldrugo F and Schadlich PK**. (1996) Alcoholism - The cost of illness in the Federal Republic of Germany. *Pharmacoeconomics* **10**: 484-493.

**Burd L, Klug MG, Coumbe MJ and Kerbeshian J**. (2003) Children and Adolescents With Attention Deficit-Hyperactivity Disorder: 1. Prevalence and Cost of Care. *Journal of Child Neurology* **18**: 555-561.

**Byford S, Barrett B, Despiegel N and Wade A**. (2011) Impact of Treatment Success on Health Service Use and Cost in Depression Longitudinal Database Analysis. *Pharmacoeconomics* **29**: 157-170.

**Carr VJ, Neil AL, Halpin SA, Holmes S and Lewin TJ**. (2003) Costs of schizophrenia and other psychoses in urban Australia: Findings from the Low Prevalence (Psychotic) Disorders Study. *Australian and New Zealand Journal of Psychiatry* **37**: 31-40.

**Casadei G, Cartabia M, Reale L, Costantino MA and Bonati M**. (2017) Italian regional health service costs for diagnosis and 1-year treatment of ADHD in children and adolescents. *International Journal of Mental Health Systems* **11**: 33.

**Chan E, Zhan C and Homer CJ**. (2002) Health care use and costs for children with attention-deficit/hyperactivity disorder: national estimates from the medical expenditure panel survey. *Archives of Pediatrics and Adolescent Medicine* **156**: 504-511.

**Chang SM, Cho SJ, Jeon HJ, Hahm BJ, Lee HJ, Park JI and Cho MJ**. (2008) Economic burden of schizophrenia in South Korea. *Journal of Korean Medical Science* **23**: 167-175.

**Chang SM, Hong JP and Cho MJ**. (2012) Economic burden of depression in South Korea. *Social Psychiatry and Psychiatric Epidemiology* **47**: 683-689.

**Chevreul K, Prigent A, Bourmaud A, Leboyer M and Durand-Zaleski I**. (2013) The cost of mental disorders in France. *European Neuropsychopharmacology* **23**: 879-886.

**Chiavegatto Filho AD, Wang YP, Campino AC, Malik AM, Viana MC and Andrade LH**. (2015) Incremental health expenditure and lost days of normal activity for individuals with mental disorders: results from the São Paulo Megacity Study. *BMC Public Health* **15**: 745.

**Chisholm D, Diehr P, Knapp M, Patrick D, Treglia M and Simon G**. (2003) Depression status, medical comorbidity and resource costs: Evidence from an international study of major depression in primary care (LIDO). *The British Journal of Psychiatry* **183**: 121-131.

**Chiu M, Lebenbaum M, Cheng J, De Oliveira C and Kurdyak P**. (2017) The direct healthcare costs associated with psychological distress and major depression: A population-based cohort study in Ontario, Canada. *PloS One* **12**: e0184268.

**Chollet J, Saragoussi D, Clay E and Francois C**. (2013) A Clinical Research Practice Datalink Analysis of Antidepressant Treatment Patterns and Health Care Costs in Generalized Anxiety Disorder. *Value in Health* **16**: 1133-1139.

**Cidav Z, Marcus SC and Mandell DS**. (2012) Implications of childhood autism for parental employment and earnings. *Pediatrics* **129**: 617-623.

**Cloutier M, Aigbogun MS, Guerin A, Nitulescu R, Ramanakumar AV, Kamat SA, DeLucia M, Duffy R, Legacy SN, Henderson C, Francois C and Wu E**. (2016) The Economic Burden of Schizophrenia in the United States in 2013. *Journal of Clinical Psychiatry* **77**: 764-771.

**Croft-Jeffreys C and Wilkinson G**. (1989) Estimated costs of neurotic disorder in UK general practice 1985. *Psychological Medicine* **19**: 549-558.

**Dams J, König H-H, Bleibler F, Hoyer J, Wiltink J, Beutel ME, Salzer S, Herpertz S, Willutzki U, Strauß B, Leibing E, Leichsenring F and Konnopka A**. (2017) Excess costs of social anxiety disorder in Germany. *Journal of Affective Disorders* **213**: 23-29.

**Das Gupta R and Guest JF**. (2002) Annual cost of bipolar disorder to UK society. *British Journal of Psychiatry* **180**: 227-233.

**de Oliveira C, Colton P, Cheng J, Olmsted M and Kurdyak P**. (2017) The direct health care costs of eating disorders among hospitalized patients: A population-based study. *International Journal of Eating Disorders* **50**: 1385-1393.

**Degli Esposti L, Sangiorgi D, Mencacci C, Spina E, Pasina C, Alacqua M and la Tour F**. (2014) Pharmaco-utilisation and related costs of drugs used to treat schizophrenia and bipolar disorder in Italy: The IBIS study. *BMC Psychiatry* **14**: 9.

**Dilsaver SC**. (2011) An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009. *Journal of Affective Disorders* **129**: 79-83.

**DuPont RL, Rice DP, Miller LS, Shiraki SS, Rowland CR and Harwood HJ**. (1996) Economic costs of anxiety disorders. *Anxiety* **2**: 167-172.

**Ekman M, Granström O, Omérov S, Jacob J and Landén M**. (2013a) The societal cost of bipolar disorder in Sweden. *Social Psychiatry and Psychiatric Epidemiology: The International Journal for Research in Social and Genetic Epidemiology and Mental Health Services* **48**: 1601-1610.

**Ekman M, Granström O, Omérov S, Jacob J and Landén M**. (2013b) The societal cost of depression: evidence from 10,000 Swedish patients in psychiatric care. *Journal of Affective Disorders* **150**: 790-797.

**Evensen S, Wisløff T, Lystad JU, Bull H, Ueland T and Falkum E**. (2015) Prevalence, employment rate, and cost of schizophrenia in a high-income welfare society: a population-based study using comprehensive health and welfare registers. *Schizophrenia Bulletin* **42**: 476-483.

**Ewest F, Reinhold T, Vloet TD, Wenning V and Bachmann CJ**. (2013) Durch Jugendliche mit Störungen des Sozialverhaltens ausgelöste Krankenkassenausgaben: Eine gesundheitsökonomische Analyse von Versichertendaten einer gesetzlichen Krankenkasse. *Kindheit und Entwicklung: Zeitschrift für Klinische Kinderpsychologie* **22**: 41-47.

**Ferry FR, Brady SE, Bunting BP, Murphy SD, Bolton D and O'Neill SM**. (2015) The Economic Burden of PTSD in Northern Ireland. *Journal of Traumatic Stress* **28**: 191-197.

**Fineberg NA, Haddad PM, Carpenter L, Gannon B, Sharpe R, Young AH, Joyce E, Rowe J, Wellsted D and Nutt DJ**. (2013) The size, burden and cost of disorders of the brain in the UK. *Journal of Psychopharmacology* **27**: 761-770.

**Fisher LJ, Goldney RD, Dal Grande E, Taylor AW and Hawthorne G**. (2007) Bipolar disorders in Australia: A population-based study of excess costs. *Social Psychiatry and Psychiatric Epidemiology: The International Journal for Research in Social and Genetic Epidemiology and Mental Health Services* **42**: 105-109.

**Fitzgerald PB, Montgomery W, de Castella AR, Filia KM, Filia SL, Christova L, Jackson D and Kulkarni J**. (2007) Australian schizophrenia care and assessment programme: Real-world schizophrenia: Economics. *Australian and New Zealand Journal of Psychiatry* **41**: 819-829.

**Florence C, Luo F, Xu L and Zhou C**. (2016) The economic burden of prescription opioid overdose, abuse and dependence in the United States, 2013. *Medical Care* **54**: 901-906.

**Frey S**. (2014) The economic burden of schizophrenia in Germany: A population-based retrospective cohort study using genetic matching. *European Psychiatry* **29**: 479-489.

**Ganz ML**. (2007) The lifetime distribution of the incremental societal costs of autism. *Archives of Pediatrics and Adolescent Medicine* **161**: 343-349.

**Gerhardt H, Heinzel-Gutenbrunner M and Bachmann CJ**. (2018) Differences in healthcare costs in youths with conduct disorders in rural vs. urban regions: an analysis of German health insurance data. *BMC Health Services Research* **18**: 714.

**Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA and Corey-Lisle PK**. (2003) The economic burden of depression in the United States: How did it change between 1990 and 2000? *Journal of Clinical Psychiatry* **64**: 1465-1475.

**Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JRT, Ballenger JC and Fyer AJ**. (1999) The economic burden of anxiety disorders in the 1990s. *Journal of Clinical Psychiatry* **60**: 427-435.

**Guest JF and Cookson RF**. (1999) Cost of schizophrenia to UK society - An incidence-based cost-of-illness model for the first 5 years following diagnosis. *Pharmacoeconomics* **15**: 597-610.

**Gupte-Singh K, Singh RR and Lawson KA**. (2017) Economic Burden of Attention-Deficit/Hyperactivity Disorder among Pediatric Patients in the United States. *Value in Health* **20**: 602-609.

**Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jennum P, Jordanova A, Jonsson L, Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercker A, Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer B, Simon R, Steinhausen HC, Stovner LJ, Vallat JM, Van den Bergh P, van Os J, Vos P, Xu W, Wittchen HU, Jonsson B, Olesen J and Group CD**. (2011) Cost of disorders of the brain in Europe 2010. *European Neuropsychopharmacology* **21**: 718-779.

**Hakkaart-van Roijen L, Zwirs BWC, Bouwmans C, Tan SS, Schulpen TWJ, Vlasveld L and Buitelaar JK**. (2007) Societal costs and quality of life of children suffering from attention deficient hyperactivity disorder (ADHD). *European Child and Adolescent Psychiatry* **16**: 316-326.

**Hall W, Goldstein G, Andrews G, Lapsley H, Bartels R and Silove D**. (1985) Estimating the economic costs of schizophrenia. *Schizophrenia Bulletin* **11**: 598-611.

**Hastrup LH, Simonsen E, Ibsen R, Kjellberg J and Jennum P**. (2019) Societal Costs of Schizophrenia in Denmark: A Nationwide Matched Controlled Study of Patients and Spouses Before and After Initial Diagnosis. *Schizophrenia Bulletin*: 68-77.

**Hawthorne G, Cheok F, Goldney R and Fisher L**. (2003) The excess cost of depression in South Australia: a population-based study. *Australian and New Zealand Journal of Psychiatry* **37**: 362-373.

**Heider D, Bernert S, Konig HH, Matschinger H, Hogh T, Brugha TS, Bebbington PE, Azorin M, Angermeyer MC and Toumi M**. (2009) Direct medical mental health care costs of schizophrenia in France, Germany and the United Kingdom - Findings from the European Schizophrenia Cohort (EuroSC). *European Psychiatry* **24**: 216-224.

**Hertzman P**. (1983) The economic costs of mental illness in Sweden 1975. *Acta Psychiatrica Scandinavica* **68**: 359-367.

**Hjortsberg C, Helldin L, Hjarthag F and Lothgren M**. (2011) Costs for Patients with Psychotic Illness: Differences Depending upon State of Remission. *Journal of Mental Health Policy and Economics* **14**: 87-93.

**Holden SE, Jenkins-Jones S, Poole CD, Morgan CL, Coghill D and Currie CJ**. (2013) The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010). *Child and Adolescent Psychiatry and Mental Health* **7**: 34.

**Hu TW, He Y, Zhang M and Chen N**. (2007) Economic costs of depression in China. *Social Psychiatry and Psychiatric Epidemiology* **42**: 110-116.

**Jarbrink K and Knapp M**. (2001) The economic impact of autism in Britain. *Autism* **5**: 7-22.

**Kilian R, Roick C, Matschinger H, Bernert S, Mory C and Angermeyer MC**. (2001) The analysis of cost structures of the treatment of schizophrenia by means of standardized assessment instruments. *Psychiatrische Praxis* **28**: S102-S108.

**Kind P and Sorensen J**. (1993) The costs of depression. *International Clinical Psychopharmacology* **7** 191–195.

**Kleine-Budde K, Muller R, Kawohl W, Bramesfeld A, Moock J and Rossler W**. (2013) The cost of depression - A cost analysis from a large database. *Journal of Affective Disorders* **147**: 137-143.

**Klora M, Zeidler J, Linder R, Verheyen F and von der Schulenburg JMG**. (2015) Costs and treatment patterns of incident ADHD patients - a comparative analysis before and after the initial diagnosis. *Health Economics Review* **5**: 40.

**Knapp M, Chisholm D, Leese M, Amaddeo F, Tansella M, Schene A, Thornicroft G, Vazquez‐Barquero JL, Knudsen HC and Becker T**. (2002) Comparing patterns and costs of schizophrenia care in five European countries: the EPSILON study. *Acta Psychiatrica Scandinavica* **105**: 42-54.

**Kortmann LM, Müller D, Simic D, Civello D and Stock S**. (2017) Disability Pension and Productivity Loss in Schizophrenia - An Empirical Analysis of the Financial Burden in Germany. *Psychiatrische Praxis* **44**: 93-98.

**Krauth C, Buser K and Vogel H**. (2002) How high are the costs of eating disorders--Anorexia nervosa and bulimia nervosa--for German society? *The European Journal of Health Economics* **3**: 244-250.

**Kujanpaa T, Ylisaukko-Oja T, Jokelainen J, Linna M and Timonen M**. (2014) Comparative cost analysis of generalized anxiety disorder and major depressive disorder patients in secondary care from a national hospital registry in Finland. *Nordic Journal of Psychiatry* **68**: 306-310.

**Laidi C, Prigent A, Plas A, Leboyer M, Fond G, Chevreul K and Face-Scz G**. (2018) Factors associated with direct health care costs in schizophrenia: Results from the FACE-SZ French dataset. *European Neuropsychopharmacology* **28**: 24-36.

**Lang H-C and Su T-P**. (2004) The cost of schizophrenia treatment in Taiwan. *Psychiatric Services* **55**: 928-930.

**Langley-Hawthorne C**. (1997) Modeling the lifetime costs of treating schizophrenia in Australia. *Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy* **19**: 1470-1495.

**Lee YC, Chatterton ML, Magnus A, Mohebbi M, Le LK and Mihalopoulos C**. (2017) Cost of high prevalence mental disorders: Findings from the 2007 Australian National Survey of Mental Health and Wellbeing. *The Australian and New Zealand Journal of Psychiatry* **51**: 1198-1211.

**Libutzki B, Ludwig S, May M, Jacobsen RH, Reif A and Hartman CA**. (2019) Direct medical costs of ADHD and its comorbid conditions on basis of a claims data analysis. *European Psychiatry* **58**: 38-44.

**Lima E and Esquerdo T**. (2003) The economic costs of alcohol misuse in Portugal. Núcleo de Investigação em Microeconomia Aplicada, Universidade do Minho.

**Lin JD, Hung WJ, Lin LP and Lai CI**. (2011) Utilization and expenditure of hospital admission in patients with autism spectrum disorder: National Health Insurance claims database analysis. *Research in Autism Spectrum Disorders* **5**: 1138-1142.

**Lin LP, Kuan CY, Hsu SW, Lee TN, Lai CI, Wu JL and Lin JD**. (2013) Outpatient visits and expenditures for children and adolescents diagnosed with autism spectrum disorders and co-occurring intellectual disability: An analysis of the national health insurance claims data. *Research in Autism Spectrum Disorders* **7**: 1625-1630.

**Ling YL, Rascati KL and Pawaskar M**. (2017) Direct and indirect costs among patients with binge‐eating disorder in the United States. *International Journal of Eating Disorders* **50**: 523-532.

**Liptak GS, Stuart T and Auinger P**. (2006) Health care utilization and expenditures for children with autism: Data from US national samples. *Journal of Autism and Developmental Disorders* **36**: 871-879.

**Lund C, Myer L, Stein DJ, Williams DR and Flisher AJ**. (2013) Mental illness and lost income among adult South Africans. *Social Psychiatry and Psychiatric Epidemiology: The International Journal for Research in Social and Genetic Epidemiology and Mental Health Services* **48**: 845-851.

**Lunsky Y, De Oliveira C, Wilton A and Wodchis W**. (2019) High health care costs among adults with intellectual and developmental disabilities: a population-based study. *Journal of Intellectual Disability Research* **63**: 124-137.

**Maercker A, Perkonigg A, Preisig M, Schaller K and Weller M**. (2013) The costs of disorders of the brain in Switzerland: an update from the European Brain Council Study for 2010. *Swiss Medical Weekly* **143**: w13751.

**Mangalore R and Knapp M**. (2007) Cost of schizophrenia in England. *Journal of Mental Health Policy and Economics* **10**: 23-41.

**Manthey J, Laramee P, Parrott S and Rehm J**. (2016) Economic burden associated with alcohol dependence in a German primary care sample: a bottom-up study. *BMC Public Health* **16**: 906.

**Mark TL, Coffey RM, King E, Harwood H, McKusick D, Genuardi J, Dilonardo J and Buck JA**. (2000) Spending on mental health and substance abuse treatment, 1987-1997. *Health Affairs* **19**: 108-120.

**Masís DP, Gómez-Restrepo C, Restrepo MU, Miranda C, Pérez A, de la Espriella M, Novoa J, Chaux A, Arenas Á, Torres N, Suárez M and Rondón M**. (2010) La carga económica de la depresión en Colombia: Costos directos del manejo intrahospitalario. *Revista Colombiana de Psiquiatría* **39**: 465-480.

**Mennini FS, Marcellusi A, Sciattella P and Pugliese A**. (2014) Pilot evaluation of indirect costs and the impact of bipolar disorder type I. *Journal of Psychopathology / Giornale di Psicopatologia* **20**: 216-222.

**Moreno JO, Bastida JL and González ALM**. (2006) The economic costs of anxiety in Spain. *Estudios de economía aplicada* **24**: 821-836.

**Nakamura K, Tanaka A and Takano T**. (1993) The social cost of alcohol abuse in Japan. *Journal of Studies on Alcohol* **54**: 618-625.

**Neil AL, Carr VJ, Mihalopoulos C, Mackinnon A and Morgan VA**. (2014) Costs of psychosis in 2010: findings from the second Australian National Survey of Psychosis. *The Australian and New Zealand Journal of Psychiatry* **48**: 169-182.

**Okumura Y and Higuchi T**. (2011) Cost of depression among adults in Japan. *Primary Care Companion to the Journal of Clinical Psychiatry* **13**.

**Olesen J, Gustavsson A, Svensson M, Wittchen HU and Jönsson B**. (2012) The economic cost of brain disorders in Europe. *European Journal of Neurology* **19**: 155-162.

**Oliva-Moreno J, López-Bastida J, Osuna-Guerrero R, Montejo-González AL and Duque-González B**. (2006) The costs of schizophrenia in Spain. *The European Journal of Health Economics* **7**: 182-188.

**Opoku-Boateng YN, Kretchy IA, Aryeetey GC, Dwomoh D, Decker S, Agyemang SA, Tozan Y, Aikins M and Nonvignon J**. (2017) Economic cost and quality of life of family caregivers of schizophrenic patients attending psychiatric hospitals in Ghana. *BMC Health Services Research* **17**: 697.

**Pamias Massana M, Crespo Palomo C, Gisbert Gelonch R and Palao Vidal DJ**. (2012) The social cost of depression in the city of Sabadell (Barcelona, Spain) (2007-2008). *Gaceta Sanitaria* **26**: 153-158.

**Pares-Badell O, Barbaglia G, Jerinic P, Gustavsson A, Salvador-Carulla L and Alonso J**. (2014) Cost of disorders of the brain in Spain. *PloS One* **9**: e105471.

**Patel A, Knapp M, Henderson J and Baldwin D**. (2002) The economic consequences of social phobia. *Journal of Affective Disorders* **68**: 221-233.

**Phanthunane P, Whiteford H, Vos T and Bertram M**. (2012) Economic burden on schizophrenia: Empirical analyses from a survey in Thailand. *Journal of Mental Health Policy and Economics* **15**: 25-32.

**Pletscher M, Mattli R, von Wyl A, Reich O and Wieser S**. (2015) The societal costs of schizophrenia in Switzerland. *Journal of Mental Health Policy and Economics* **18**: 93-103.

**Quintero J, Ramos-Quiroga JA, Sebastian JS, Montanes F, Fernandez-Jaen A, Martinez-Raga J, Giral MG, Graell M, Mardomingo MJ, Soutullo C, Eiris J, Tellez M, Pamias M, Correas J, Sabate J, Garcia-Orti L and Alda JA**. (2018) Health care and societal costs of the management of children and adolescents with attention-deficit/hyperactivity disorder in Spain: a descriptive analysis. *BMC Psychiatry* **18**: 40.

**Rice DP and Miller LS**. (1998) Health economics and cost implications of anxiety and other mental disorders in the United States. *The British Journal of Psychiatry* **173**: 4-9.

**Ritter A, Chalmers J and Berends L**. (2015) Health expenditure on alcohol and other drug treatment in Australia (2012/2013). *Drug and Alcohol Review* **34**: 397-403.

**Rouillon F, Toumi M, Dansette G-Y, Benyaya J and Auquier P**. (1997) Some aspects of the cost of schizophrenia in France. *Pharmacoeconomics* **11**: 578-594.

**Rovira J, Albarracin G, Salvador L, Rejas J, Sánchez-Iriso E and Cabasés JM**. (2012) The cost of generalized anxiety disorder in primary care settings: Results of the ANCORA study. *Community Mental Health Journal* **48**: 372-383.

**Runge C and Grunze H**. (2004) Jährliche Krankheitskosten bipolarer Störungen in Deutschland. *Der Nervenarzt* **75**: 896-903.

**Sado M**. (2014) The economic burden of depression - study for cost of depression. *Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica* **116**: 107-115.

**Sado M, Inagaki A, Koreki A, Knapp M, Kissane LA, Mimura M and Yoshimura K**. (2013) The cost of schizophrenia in Japan. *Neuropsychiatric Disease and Treatment* **9**: 787-798.

**Salvador-Carulla L, Bendeck M, Fernandez A, Alberti C, Sabes-Figuera R, Molina C and Knapp M**. (2011) Costs of depression in Catalonia (Spain). *Journal of Affective Disorders* **132**: 130-138.

**Salvador-Carulla L, Bendeck M, Ferrer M, Andión Ó, Aragonès E and Casas M**. (2014) Cost of borderline personality disorder in Catalonia (Spain). *European Psychiatry* **29**: 490-497.

**Samnaliev M, Noh HL, Sonneville KR and Austin SB**. (2015) The economic burden of eating disorders and related mental health comorbidities: An exploratory analysis using the U.S. Medical Expenditures Panel Survey. *Preventive Medicine Reports* **2**: 32-34.

**Sandelin R, Kowalski J, Ahnemark E and Allgulander C**. (2013) Treatment patterns and costs in patients with generalised anxiety disorder: One-year retrospective analysis of data from national registers in Sweden. *European Psychiatry* **28**: 125-133.

**Sarlon E, Heider D, Millier A, Azorin JM, Konig HH, Hansen K, Angermeyer MC, Aballea S and Toumi M**. (2012) A prospective study of health care resource utilisation and selected costs of schizophrenia in France. *BMC Health Services Research* **12**: 269.

**Schlander M**. (2007) Impact of attention-deficit/hyperactivity disorder (ADHD) on prescription drug spending for children and adolescents: Increasing relevance of health economic evidence. *Journal of Mental Health Policy and Economics* **10**: S39-S39.

**Schofield DJ, Shrestha RN, Percival R, Passey ME, Callander EJ and Kelly SJ**. (2011) The personal and national costs of mental health conditions: impacts on income, taxes, government support payments due to lost labour force participation. *BMC Psychiatry* **11**: 72.

**Sharma P, Das SK and Deshpande SN**. (2006) An estimate of the monthly cost of two major mental disorders in an Indian metropolis. *Indian Journal of Psychiatry* **48**: 143-148.

**Shei A, Hirst M, Kirson NY, Enloe CJ, Birnbaum HG and Dunlop WC**. (2015) Estimating the health care burden of prescription opioid abuse in five European countries. *Clinicoecon Outcomes Res* **7**: 477-488.

**Shirneshan E**. (2014) Cost of illness study of anxiety disorders for the ambulatory adult population of the united states. *University of Tennessee Health Science Center.*

**Slomp M, Jacobs P, Ohinmaa A, Bland R, Block R, Dewa CS and Wang C**. (2012) The distribution of mental health service costs for depression in the Alberta population. *The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie* **57**: 564-569.

**Smit F, Cuijpers P, Oostenbrink J, Batelaan N, de Graaf R and Beekman A**. (2006) Costs of nine common mental disorders: Implications for curative and preventive psychiatry. *Journal of Mental Health Policy and Economics* **9**: 193-200.

**Sobocki P, Lekander I, Borgstrom F, Strom O and Runeson B**. (2007) The economic burden of depression in Sweden from 1997 to 2005. *European Psychiatry* **22**: 146-152.

**Soeteman DI, Hakkaart-van Roijen L, Verheul R and Busschbach JJV**. (2008) The economic burden of personality disorders in mental health care. *Journal of Clinical Psychiatry* **69**: 259-265.

**Souêtre E, Lozet H, Cimarosti I, Martin P, Chignon JM, Adés J, Tignol J and Darcourt G**. (1994) Cost of anxiety disorders: Impact of comorbidity. *Journal of Psychosomatic Research* **38**: 151-160.

**Stoudemire A, Frank R, Hedemark N, Kamlet M and Blazer D**. (1986) The Economic Burden of Depression. *General Hospital Psychiatry* **8**: 387-394.

**Strydom A, Romeo R, Perez-Achiaga N, Livingston G, King M, Knapp M and Hassiotis A**. (2010) Service use and cost of mental disorder in older adults with intellectual disability. *The British Journal of Psychiatry* **196**: 133-138.

**Stuhldreher N, Konnopka A, Wild B, Herzog W, Zipfel S, Lowe B and Konig HH**. (2012) Cost-of-illness studies and cost-effectiveness analyses in eating disorders: a systematic review. *International Journal of Eating Disorders* **45**: 476-491.

**Suleiman TG, Ohaeri JU, Lawal RA, Haruna AY and Orija OB**. (1997) Financial cost of treating out-patients with schizophrenia in Nigeria. *The British Journal of Psychiatry* **171**: 364-368.

**Sundhedsministeriet [Ministry of Health]**. (1999) De samfundsøkonomiske konsekvenser af alkoholforbrug [The economic consequences of alcohol consumption in Denmark]. Copenhagen, Denmark: Ministry of Health.

**Telford C, Green C, Logan S, Langley K, Thapar A and Ford T**. (2013) Estimating the costs of ongoing care for adolescents with attention-deficit hyperactivity disorder. *Social Psychiatry and Psychiatric Epidemiology: The International Journal for Research in Social and Genetic Epidemiology and Mental Health Services* **48**: 337-344.

**Teoh SL, Chong HY, Aziz SA, Chemi N, Othman AR, Zaki NM, Vanichkulpitak P and Chaiyakunapruk N**. (2017) The economic burden of schizophrenia in Malaysia. *Neuropsychiatric Disease and Treatment* **13**: 1979-1987.

**Thomas CM and Morris S**. (2003) Cost of depression among adults in England in 2000. *The British Journal of Psychiatry* **183**: 514-519.

**Tiainen A and Rehnberg C**. (2010) The economic burden of psychiatric disorders in Sweden. *International Journal of Social Psychiatry* **56**: 515-526.

**Tomonaga Y, Haettenschwiler J, Hatzinger M, Holsboer-Trachsler E, Rufer M, Hepp U and Szucs TD**. (2013) The Economic Burden of Depression in Switzerland. *Pharmacoeconomics* **31**: 237-250.

**Trivedi DN, Lawrence LW, Blake SG, Rappaport HM and Feldbaus JB**. (2004) Study of the economic burden of depression. *Journal of Pharmaceutical Finance, Economics and Policy* **13**: 51-66.

**Trogdon JG, Murphy LB, Khavjou OA, Li R, Maylahn CM, Tangka FK, Nurmagambetov TA, Ekwueme DU, Nwaise I, Chapman DP and Orenstein D**. (2015) Costs of Chronic Diseases at the State Level: The Chronic Disease Cost Calculator. *Preventing Chronic Disease* **12**: E140.

**Vasiliadis H-M, Dionne P-A, Préville M, Gentil L, Berbiche D and Latimer E**. (2013) The excess healthcare costs associated with depression and anxiety in elderly living in the community. *The American Journal of Geriatric Psychiatry* **21**: 536-548.

**Vazquez-Polo FJ, Negrin M, Cabases JM, Sanchez E, Haro JM and Salvador-Carulla L**. (2005) An analysis of the costs of treating schizophrenia in Spain: A hierarchical Bayesian approach. *Journal of Mental Health Policy and Economics* **8**: 153-165.

**Vodušek DB, Kos M, Dolenc VV, Tomori M, Neubauer D and Sobocki P**. (2008) Cost of disorders of the brain in Slovenia. *Slovenian Medical Journal* **77**: 164-175.

**Wagner CJ, Metzger FG, Sievers C, Marschall U, L'Hoest H, Stollenwerk B and Stock S**. (2016) Depression-related treatment and costs in Germany: Do they change with comorbidity? A claims data analysis. *Journal of Affective Disorders* **193**: 257-266.

**Wancata J, Sobocki P and Katschnig H**. (2007) Cost of disorders of the brain in Austria in the year 2004. *Wiener Klinische Wochenschrift* **119**: 91-98.

**Young AH, Rigney U, Shaw S, Emmas C and Thompson JM**. (2011) Annual cost of managing bipolar disorder to the UK healthcare system. *Journal of Affective Disorders* **133**: 450-456.

**Zeidler J, Slawik L, Fleischmann J and Greiner W**. (2012) The costs of schizophrenia and predictors of hospitalisation from the statutory health insurance perspective. *Health Economics Review* **2**: 9.

**Zuvekas SH and Meyerhoefer CD**. (2009) State variations in the out-of-pocket spending burden for outpatient mental health treatment. *Health Affairs* **28**: 713-722.

**Ösby U, Tiainen A, Backlund L, Edman G, Adler M, Hällgren J, Sennfält K, van Baardewijk M and Sparen P**. (2009) Psychiatric admissions and hospitalization costs in bipolar disorder in Sweden. *Journal of Affective Disorders* **115**: 315-322.